OncLive TV

Brad S. Kahl, MD, discusses how BTK inhibitors and MRD-guided treatment may help patients with frontline mantle cell lymphoma avoid transplantation.

Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how the treatment may reduce treatment burden for patients with polycythemia vera.

Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant and the clinical role of the ctDNA-guided switch paradigm introduced by SERENA-6.

Shimoli Barot, MD, considers how palbociclib maintenance could be sequenced with frontline T-DXd plus pertuzumab in HER2-positive metastatic breast cancer.

Ja Min Byun, MD, PhD, discusses response consistency and the future of mezigdomide plus elranatamab in multiple myeloma.

Ja Min Byun, MD, PhD, discusses updated phase 1 findings with mezigdomide plus elranatamab in relapsed/refractory multiple myeloma.

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, explains how safety, resistance, and sequencing guide frontline therapy selection in CLL.

Shimoli Barot, MD, discusses PATINA data showing improved PFS with palbociclib-based maintenance in HR-positive, HER2-positive metastatic breast cancer.

Brad S. Kahl, MD, discusses how the TRIANGLE trial supports frontline therapy without autologous transplantation in mantle cell lymphoma.

Zev A. Wainberg, MD, discusses the phase 3 DAWN-303 trial of INCB161734 plus chemotherapy and the expanding role of KRAS inhibitors in pancreatic cancer.

Lucy Gilbert, MD, MSc, FRCOG, discusses data from the ROSELLA trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Prithviraj Bose, MD, discusses spleen response and early survival data from the phase 3 SENTRY trial in JAK inhibitor-naive myelofibrosis.

William N. William Jr, MD, discusses the design, toxicity lessons, and TP53 co-mutant signal from the phase 2 AMIGO-1 trial of amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.

Andrew Kuykendall, MD, discusses how hepcidin-upregulating agents could transform hematocrit control for patients with polycythemia vera.

Giada Bianchi, MD, discusses the design of the phase 3 CARES program evaluating anselamimab in AL amyloidosis.

Tapan M. Kadia, MD, details the dosing, tolerability, and response data with the use of dibotatug in patients with large granular lymphocytic leukemia.

Giada Bianchi, MD, discusses the mechanism of action for anselamimab in AL amyloidosis.

Gabriela S. Hobbs, MD, discusses how to distinguish proliferative from cytopenic myelofibrosis and the role of risk stratification.

Julia K. Rotow, MD, discusses why dual EGFR inhibition prevented acquired resistance mutations but did not extend PFS, and where the combination fits now.

Laura Alder, MD, discusses a retrospective analysis in which early-morning tarlatamab infusions during cycle 1 did not improve outcomes in small cell lung cancer, and what a prospective test would require.

Laura Alder, MD, discusses a multi-institutional real-world analysis of local consolidation and continued tarlatamab in patients with oligoprogressive small cell lung cancer.

Julia K. Rotow, MD, discusses how T-DXd, zongertinib, and sevabertinib may be sequenced in first-line HER2-mutant NSCLC and why resistance profiling at progression matters.

Julia K. Rotow, MD, discusses subgroup results and post-progression treatment imbalances in the phase 3 DESTINY-Lung04 trial of first-line T-DXd in HER2-mutant NSCLC.

Alexander Drilon, MD, discusses future directions for zidesamtinib in TKI-naive, ROS1-positive NSCLC following the ARROS-1 trial.

Alexander Drilon, MD, discusses phase 1/2 ARROS-1 efficacy and safety findings with zidesamtinib in TKI-naive, ROS1-positive NSCLC.

David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.

David R. Gandara, MD, discusses why KRAS G12C predicted outsized benefit with first-line cemiplimab in PD-L1–high NSCLC and what it means for trial design.

Luis E. Raez, MD, discusses how oral TKIs may shift frontline sequencing across ROS1-positive, HER2-mutant, and EGFR exon 20 insertion–positive NSCLC.

Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.

Rajwanth R. Veluswamy, MD, MSCR, discusses universal KRAS testing, the frontline immunotherapy signal in KRAS G12C+ NSCLC, and next-generation G12C inhibitors.